HALOZYME THERAPEUTICS INC (HALO)

Halozyme Therapeutics posted a strong Q1 2026 with revenue up 42.2% to $376.7M, beating analyst estimates. The company announced a $1B buyback program and secured three new licensing deals, boosting long-term royalty prospects through the 2040s.

The search for HALO stocks is a hot theme in the stock market. There is now an ETF to invest in it.

The cosmetics maker reported fiscal fourth-quarter net sales of $449.3 million, a 35% increase from a year earlier.

Why Halozyme Therapeutics (HALO) Is Drawing Investor Attention Now Halozyme Therapeutics (HALO) is back on investors’ radar after a period of mixed share performance, with the stock roughly flat over the past month but lower over the past 3 months. See our latest analysis for Halozyme ...

Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the expanding adoption of subcutaneous drug delivery through its ENHANZE technology. CEO Helen Torley credited the quarter’s momentum to ...